The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

X-Elio will supply 245GWh of clean energy annually to four pharmaceutical companies through its Lorca Solar project.